SB269970 free base

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: SB269970 free base
• 英文别名: 3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol
• 化学式: C₁₈H₂₈N₂O₃S
• 分子量: 352.5
• InChiKey: HWKROQUZSKPIKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  69.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
  申请人：——

  公开号：US20040039044A1

  公开（公告）日：2004-02-26

  Novel aminoalkylpyrrolidine 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了新型氨基烷基吡咯啉5-HT7受体配体，制备这种配体的方法，用于制备受体配体的中间化合物，包括受体配体的药物组合物，以及利用受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。受体配体具有如下式（1）：其中式中的变量如本文所定义，并且包括其药用可接受的盐、溶剂化合物、活性代谢物或前药。
• Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
  申请人：——

  公开号：US20040044037A1

  公开（公告）日：2004-03-04

  Novel amidino-urea 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了一种新型的胍基脲5-HT7受体配体，以及制备这种配体的方法、在配体制备中有用的中间化合物、包括该受体配体的药物组合物，以及利用该受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。该受体配体具有化学式（1）：其中化学式变量如本文所定义，以及其药用盐、溶剂合物、活性代谢产物或前药。
• Synthesis by chiral diamine-mediated asymmetric alkylation
  申请人：Deng Xiaohu

  公开号：US20060069250A1

  公开（公告）日：2006-03-30

  Chiral synthesis from an achiral starting material by chiral diamine-mediated, such as sparteine-mediated, intermolecular asymmetric alkylation with a strained cyclic ether in the presence of a Lewis acid.

  在Lewis酸存在的情况下，通过手性二胺介导的手性合成（例如sparteine介导），从非手性起始物质进行分子间不对称烷基化，使用受限环醚。
• Therapeutic agent for intestinal diseases and visceral pain
  申请人：Tokumasu Munetaka

  公开号：US20050148632A1

  公开（公告）日：2005-07-07

  The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety:

  本发明涉及一种治疗腹泻型肠易激综合征、溃疡性结肠炎、内脏疼痛或腹痛的治疗剂，其含有以下公式的化合物或其类似物，具有5-HT7受体拮抗作用；该治疗剂具有优异的治疗效果和高安全性：
• Pyrrole Derivative or Salt Thereof
  申请人：Seo Ryushi

  公开号：US20090036421A1

  公开（公告）日：2009-02-05

  [Problem] To provide a compound which may be used for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS). [Means for Resolution] It was found that a pyrrole derivative characterized by the possession of a guanidinocarbonyl group or amido group as a substituent group at the 3-position, or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT 2B receptor and 5-HT 7 receptor. In addition, the compound of the present invention having the antagonistic activity for both of the receptors showed a good pharmacological action in comparison with the case in which an antagonist selective for either one of the receptors was used alone. Based on the above, the compound of the present invention is useful for the prevention and/or treatment of diseases in which 5-HT 2B receptor and 5-HT 7 receptor are concerned, particularly for the treatment of irritable bowel syndrome (IBS).

  [问题] 提供一种可用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是治疗肠易激综合征（IBS）的化合物。 [解决方案] 发现一种吡咯衍生物，在其3位具有胍基甲酰基基团或酰胺基团作为取代基团，或其药学上可接受的盐，具有对5-HT2B受体和5-HT7受体的强拮抗作用。此外，与仅使用对其中一种受体选择性拮抗剂相比，具有对两种受体拮抗活性的本发明化合物显示出良好的药理作用。基于上述，本发明化合物对于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病，特别是治疗肠易激综合征（IBS）是有用的。